(Q39577659)

13 September 2017

Basic Mechanisms of Chemotherapy (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

18 November 2022

1 reference

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

18 November 2022

author name string

D. A. Mitchison

1

1 reference

PubMed ID

92392

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A92392

18 November 2022

language of work or name

English

0 references

publication date

1 December 1979

1 reference

PubMed ID

92392

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S0012369216393849?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

https://api.elsevier.com/content/article/PII:S0012369216393849?httpAccept=text/plain

18 November 2022

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

18 November 2022

1 reference

13 September 2017

76

1 reference

13 September 2017

771-781

1 reference

13 September 2017

6 Suppl

1 reference

A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: second report

13 September 2017

2

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--third investigation: the effect of an initial streptomycin supplement

18 November 2022

6

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India

18 November 2022

7

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India

18 November 2022

8

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Streptomycin plus thiacetazone (thioacetazone) compared with streptomycin plus PAS and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in Rhodesia

18 November 2022

11

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Streptomycin plus pyrazinamide in the treatment of patients excreting isonazid-resistant tubercle bacilli, following previous chemotherapy.

18 November 2022

12

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.

18 November 2022

13

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues

18 November 2022

15

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli

18 November 2022

16

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results

18 November 2022

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol

18 November 2022

19

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Bactericidal Activity of Streptomycin, Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Alone and In Combination Against Mycobacterium Tuberculosis1

18 November 2022

20

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

A selective oleic acid albumin agar medium for tubercle bacilli

18 November 2022

21

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis

18 November 2022

22

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Laboratory aspects of intermittent drug therapy

18 November 2022

23

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Studies on the treatment of experimental tuberculosis of the guinea pig with intermittent doses of isoniazid

18 November 2022

24

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

Cumulative effects of pulsed exposures of mycobacterium tuberculosis to isoniazid.

18 November 2022

25

1 reference

https://api.crossref.org/works/10.1378/CHEST.76.6_SUPPLEMENT.771

18 November 2022

Identifiers

1 reference

13 September 2017

1 reference

PubMed ID

92392